ZILBRYSQ Drug Patent Profile

Which patents cover Zilbrysq, and what generic alternatives are available?

Zilbrysq is a drug marketed by Ucb Inc and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and fifty-five patent family members in thirty-three countries.

The generic ingredient in ZILBRYSQ is zilucoplan sodium. One supplier is listed for this compound. Additional details are available on the zilucoplan sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zilbrysq

Zilbrysq will be eligible for patent challenges on October 17, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 12, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZILBRYSQ

International Patents:	155
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for ZILBRYSQ
What excipients (inactive ingredients) are in ZILBRYSQ?	ZILBRYSQ excipients list
DailyMed Link:	ZILBRYSQ at DailyMed

See drug prices for ZILBRYSQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZILBRYSQ

NDA:

216834

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZILBRYSQ

Drug Class	Complement Inhibitor
Mechanism of Action	Complement Inhibitors

US Patents and Regulatory Information for ZILBRYSQ

ZILBRYSQ is protected by nine US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes			Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes			Y

International Patents for ZILBRYSQ

When does loss-of-exclusivity occur for ZILBRYSQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZILBRYSQ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015274482
Australia	2019200828
Australia	2021204313
Brazil	112016029076

Supplementary Protection Certificates for ZILBRYSQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3154561	CA 2024 00021	Denmark		PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204
3154561	301275	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
3154561	PA2024514	Lithuania		PRODUCT NAME: ZILUKOPLANAS; REGISTRATION NO/DATE: EU/1/23/1764 20231201
3154561	LUC00343	Luxembourg		PRODUCT NAME: ZILUCOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1764 20231204

ZILBRYSQ market dynamics and financial trajectory: sales outlook, payer adoption, exclusivity and competitive threats

Last updated: July 29, 2026

ZILBRYSQ is commercially active and monetization is tied to (1) net price and rebate structure in the US, (2) payer coverage policy and prior authorization behavior, and (3) how quickly prescribers shift from existing standards of care. The sales ramp and forward revenue trajectory will be constrained primarily by pricing pressure from managed care and by the timing of competitive entry risk against the product’s patent and exclusivity wall.

What is ZILBRYSQ and where does it sit in the competitive landscape?

Featured snippet answer: ZILBRYSQ’s market position depends on its FDA-labeled indication(s), route of administration, and whether it is first-in-class or positioned as a differentiated option within a crowded therapeutic category.

What are the labeled uses that drive demand?

Demand is a function of patient pool size and treatment frequency. For a market-share forecast, the key drivers are:

• Indication breadth (all eligible subpopulations vs restricted labeling)
• Dosing schedule frequency (monthly vs daily vs episodic)
• Lines of therapy placement (first-line penetration vs later-line limitation)

How does ZILBRYSQ compete against existing standards of care?

Competitive dynamics typically hinge on:

• Clinical differentiation (efficacy/safety package and tolerability)
• Site-of-care (outpatient clinic vs specialty pharmacy vs hospital)
• Administrative burden (prior auth and step therapy complexity)
• Total cost of therapy after rebates

How strong are sales traction signals for ZILBRYSQ?

Featured snippet answer: Commercial traction for ZILBRYSQ should be evaluated against (1) prescription velocity, (2) pull-through from specialty pharmacy networks, and (3) net-to-gross and rebate intensity relative to peers in the same therapeutic class.

What determines early adoption speed?

Early adoption typically correlates with:

• Formulary tiering (preferred vs non-preferred)
• Time to formulary inclusion after launch
• Manufacturer contracting strategy with pharmacy benefit managers
• Specialty distribution capacity and patient support program effectiveness

How do net price and rebates affect revenue, not just topline prescriptions?

Revenue trajectory in pharma is rarely linear with unit growth. For ZILBRYSQ:

• Net sales are shaped by rebate magnitude, including Medicaid and commercial rebate offers
• Gross-to-net compression accelerates when payers demand parity with competitors
• Patient assistance programs can mask net pressure by boosting patient access

When does ZILBRYSQ face exclusivity risk and generic entry threats?

Featured snippet answer: Generic and biosimilar risk depends on patent term and regulatory exclusivity timing tied to ZILBRYSQ’s NDA/BLA reference and patent estate.

Patent wall and exclusivity timing: what to model

A forward financial model should treat risk as a staged process:

1. Near-term: payer tightening and contracting adjustments (pre-competition)
2. Mid-term: Paragraph IV filings and litigation (if applicable)
3. Launch window: first generic launch or authorized generics (if any)
4. Post-launch: share erosion driven by price competition

What is the most likely competitive entry scenario?

For market dynamics, the critical question is whether the entry comes as:

• A single authorized generic or first-to-market generic with settlement leverage
• Multiple Paragraph IV filers creating faster erosion
• A label expansion by competitors reducing ZILBRYSQ’s incremental addressable share

What patents protect ZILBRYSQ and how many are in its estate?

Featured snippet answer: ZILBRYSQ’s defensibility is measured by the number and durability of Orange Book-listed patents, split across composition-of-matter, formulation, and method-of-use (if applicable).

How to categorize patent coverage for revenue protection

In financial terms, different patent types drive different erosion profiles:

• Composition-of-matter: tends to be the longest-lived barrier
• Formulation patents: can block switch to certain generics with same API but different formulation
• Method-of-use patents: can restrict “indication switching” even after off-label erosion begins

How do filing dates map to expiry risk?

Model using three clocks:

• Patent expiry by jurisdiction
• Regulatory exclusivity expiry (NCE, 5-year, pediatric, orphan where applicable)
• Litigation over patent validity and infringement

What Orange Book status does ZILBRYSQ have and what does it imply for generic strategy?

Featured snippet answer: Orange Book listings define the legal surface area for generic entry. The combination of active patents and those expiring earliest determines filing strategy and likely launch timing.

How generic applicants decide whether to file

Paragraph IV incentives increase when:

• Early expiration patents are clearly infringed (and easier to litigate)
• There are multiple weak patents that can be invalidated quickly
• Settlement leverage is plausible based on litigation cost economics

What does settlement history usually mean for timelines?

Where settlements are used, generic launch is often delayed even if FDA approval occurs. A revenue model should:

• Treat settlement as an imposed entry date cap
• Separate approval date from first commercial shipment date

What formulation and method-of-use patents could block “designed around” competition?

Featured snippet answer: If ZILBRYSQ’s commercial differentiation depends on delivery system or specific dosing behavior, formulation patents can slow competition even when composition-of-matter barriers weaken.

Common formulation patent mechanisms that affect economics

Potential constraints include:

• Release profile requirements (if extended-release or special-release)
• Particle size, polymorph, salt form control
• Stability and manufacturing process definitions that affect generic bioequivalence

Method-of-use patents and payer behavior

Method-of-use coverage can reduce:

• Indication-driven patient switching
• Payer incentives to cover the generic for specific labeled uses

Which companies are challenging ZILBRYSQ and what is the litigation status?

Featured snippet answer: Patent litigation posture affects launch likelihood and market-share loss timing. The highest-information items are filing counts, court outcomes, and any settlement dates.

How to read litigation for financial forecasting

For ZILBRYSQ, the key variables are:

• Whether litigated patents include core composition-of-matter
• Claim construction outcomes that signal strength or weakness
• Permanent injunction risk vs license-through risk

How does FDA regulatory status affect ZILBRYSQ revenue trajectory?

Featured snippet answer: Revenue is sensitive to regulatory milestones when they influence access, label scope, or competitive timing.

What matters in the FDA pathway

Financially relevant FDA elements include:

• Approval date and initial exclusivity start
• Label scope and post-marketing expansions
• REMS requirements (if any), which can constrain prescribing dynamics

What happens if ZILBRYSQ expands its label?

A label expansion can change:

• Eligibility and patient pool
• Payer policy
• Competitive intensity (new subgroups may have existing preferred therapies)

What is the payer adoption curve expected to look like?

Featured snippet answer: Adoption typically transitions from early access to broader formulary inclusion. The slope of that curve depends on rebate aggressiveness, contracting terms, and whether competitors undercut with lower net pricing.

Managed care dynamics that compress net sales

For ZILBRYSQ, anticipate pressure from:

• PBM formulary decisions
• Therapeutic substitution and step edits
• MAC-style dynamics for administered medicines (if relevant to delivery model)

Specialty pharmacy and channel mix

Revenue is impacted by channel:

• Specialty pharmacy dispense patterns
• Institutional channel share
• Out-of-pocket support participation rates

How does ZILBRYSQ compare with close competitors on pricing and adoption risk?

Featured snippet answer: The strongest predictor of revenue under uncertainty is the relative net price versus peers adjusted for rebates and patient support.

Competitive comparison framework

A practical comparison table for forecasting should include:

• Labeled indication overlap
• Dosing frequency and duration
• List price and estimated net price after rebates
• Coverage likelihood and prior auth friction
• Patent expiry proximity for each competitor

Share erosion modeling after first generic entry

Use a staged penetration curve:

• Phase 1: initial generic share capture through formulary updates
• Phase 2: price competition accelerates net-to-gross compression
• Phase 3: broader substitution after payer policy stabilization

What manufacturing and IP barriers could delay competition?

Featured snippet answer: Even when patent barriers weaken, manufacturing readiness and regulatory chemistry controls can delay generic uptake.

Key barriers that affect time-to-market

• Bioequivalence feasibility for complex release profiles
• Control of impurities and stability characteristics
• Scale-up and validation timelines
• Any process patents tied to commercial manufacturing

Key financial trajectory scenarios for ZILBRYSQ

Featured snippet answer: Build three scenarios: base case without rapid competitive erosion, downside case with accelerated payer compression, and severe downside with earlier-than-expected entry from legal or regulatory events.

Base case: orderly adoption with manageable net price pressure

Assumptions:

• Continued formulary inclusion progression
• Rebates remain within a survivable range versus peers
• No major label restriction

Downside: rapid rebate expansion and utilization controls

Assumptions:

• PBM tactics intensify
• Prior authorization volume increases
• Step therapy blocks access for new starts

Severe downside: competitive erosion driven by litigation outcomes or earlier entry

Assumptions:

• Patent or exclusivity barrier weakens
• First generic or authorized competitor enters earlier
• Share shift forces a net price reset

Key Takeaways

• ZILBRYSQ’s financial trajectory is driven more by net pricing, payer access, and rebate intensity than by unit growth alone.
• The market’s high-impact variable is the timing and strength of ZILBRYSQ’s patent and exclusivity wall, which determines whether competitive entry occurs in a single step or via earlier erosion signals.
• Forecasts should model staged risk: pre-competition contracting pressure first, then litigation-shaped entry timing, then post-launch share and net price compression.
• The payer adoption curve is a revenue slope determinant: formulary tiering and prior authorization behavior will dominate near-term performance.

FAQs

1. How does ZILBRYSQ’s net-to-gross ratio typically change after formulary tier reassignment?
2. What is the typical revenue impact of prior authorization tightening for specialty drugs like ZILBRYSQ?
3. How do Paragraph IV filings against ZILBRYSQ influence FDA approval timing versus actual market entry?
4. What contract terms with PBMs most affect ZILBRYSQ’s unit economics during the first 24 months post-launch?
5. How should investors model ZILBRYSQ revenue downside if label expansions increase competitive overlap?

References

1. APA: FDA Orange Book. U.S. Food and Drug Administration. (Accessed via FDA database).
2. APA: FDA Drug Approval Reports and labeling information for ZILBRYSQ. U.S. Food and Drug Administration. (Accessed via FDA database).

DrugChatter Q&A for ZILBRYSQ

Zilbrysq cancer statistics?
Mechanism of action for zilbrysq?
Best time to take zilbrysq?
What are the differences between zilbrysq and competitor e?
Mechanism of action of zilbrysq?